Recombinant Human DNAM-1/CD226 Fc Chimera (Catalog # 666-DN)
Measured by its ability to neutralize DNAM‑1-mediated adhesion of the COLO 205 human colorectal adenocarcinoma cell line. Shibuya, A. et al. (1996) Immunity 4:573. The Neutralization Dose (ND50) is typically 0.5-1.5 µg/mL in the presence of 20 µg/mL Recombinant Human DNAM-1/CD226 Fc Chimera.
Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Cell Adhesion Mediated by DNAM-1/CD226 and Neutralization by Human DNAM-1/ CD226 Antibody.
Recombinant Human DNAM-1/CD226 Fc Chimera (Catalog # 666-DN), immobilized onto a microplate, supports the adhesion of the COLO 205 human colorectal adenocarcinoma cell line in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human DNAM‑1/CD226 Fc Chimera (20 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human DNAM‑1/ CD226 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF666). The ND50 is typically 0.5‑1.5 µg/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
Reconstitution Buffer Available
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
DNAX accessory molecule-1 (DNAM-1), also known as CD226, is a 65 kDa type I transmembrane glycoprotein in the immunoglobulin superfamily (1). Mature human DNAM-1 contains a 236 amino acid (aa) extracellular domain (ECD) with two Ig-like C2-set domains and a 61 aa cytoplasmic region that contains motifs for binding PDZ domains and band 4.1 family proteins (1, 2). Within the ECD, human DNAM-1 shares 50% and 52% aa sequence identity with mouse and rat DNAM-1, respectively. DNAM-1 is expressed on multiple lymphoid and myeloid cells and interacts with CD155/PVR and Nectin-2/CD112 (3, 4). Ligation of DNAM-1 promotes the activation of NK cells, CD8+ T cells, and mast cells (2‑6), dendritic cell maturation, megakaryocyte and activated platelet adhesion to vascular endothelial cells, and monocyte extravasation; it inhibits the forrmation of osteoclasts (7‑10). Platelet-endothelium interactions mediated by DNAM-1 enable the metastasis of tumor cells to the lung (11). In activated, but not in resting NK, T, and mast cells, the cis association of DNAM-1 with CD18 contributes to the tyrosine and serine phosphorylation of DNAM-1 during activation (6, 9, 12‑14).
Fuchs, A. and M. Colonna (2006) Semin. Cancer Biol. 16:359.
Shibuya, A. et al. (1996) Immunity 4:573.
Bottino, C. et al. (2003) J. Exp. Med. 198:557.
Tahara-Hanaoka, S. et al. (2004) Int. Immunol. 16:533.
Dardalhon, V. et al. (2005) J. Immunol. 175:1558.
Bachelet, I. et al. (2006) J. Biol. Chem. 281:27190.
Reymond, N. et al. (2004) J. Exp. Med. 199:1331.
Kakehi, S. et al. (2007) Mol. Cell. Biochem. 301:209.
Kojima, H. et al. (2003) J. Biol. Chem. 278:36748.
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.